Clinical Trials Logo

Stage III/IV Melanoma clinical trials

View clinical trials related to Stage III/IV Melanoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03132675 Active, not recruiting - Clinical trials for Stage III/IV Melanoma

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment

Keynote-695
Start date: October 3, 2017
Phase: Phase 2
Study type: Interventional

Keynote 695 is Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab or nivolumab.